ENTRY       D12152                      Drug
NAME        Eluvixtamab (USAN)
FORMULA     C2396H3620N658O764S15
EXACT_MASS  54314.0451
MOL_WEIGHT  54347.3052
SEQUENCE    QVQLVQSGAE VKKPGESVKV SCKASGYTFT NYGMNWVKQA PGQGLEWMGW NTYTGEPTY
            ADKFQGRVTM TTDTSTSTAY MEIRNLGGDD TAVYYCARWS WSDGYYVYFD YWGQGTSVTV
            SSGGGGSGGG GSGGGGSDIV MTQSPDSLTV SLGERTTINC KSSQSVLDSS TNKNSLAWYQ
            QKPGQPPKLL LSWASTRESG IPDRFSGSGS GTDFTLTIDS PQPEDSATYY CQQSAHFPIT
            FGQGTRLEIK SGGGGSEVQL VESGGGLVQP GGSLKLSCAA SGFTFNKYAM NWVRQAPGKG
            LEWVARIRSK YNNYATYYAD SVKDRFTISR DDSKNTAYLQ MNNLKTEDTA VYYCVRHGNF
            GNSYISYWAY WGQGTLVTVS SGGGGSGGGG SGGGGSQTVV TQEPSLTVSP GGTVTLTCGS
            STGAVTSGNY PNWVQQKPGQ APRGLIGGTK FLAPGTPARF SGSLLGGKAA LTLSGVQPED
            EAEYYCVLWY SNRWVFGGGT KLTVLHHHHH H
            (Disulfide bridge: 22-96, 160-231, 278-354, 418-486)
  TYPE      Peptide
EFFICACY    Antineoplastic
  TYPE      Monoclonal antibody
COMMENT     Treatment of acute myeloid leukemia (AML)
TARGET      CD33 (SIGLEC3) [HSA:945] [KO:K06473]
  PATHWAY   hsa04640(945)  Hematopoietic cell lineage
BRITE       Target-based classification of drugs [BR:br08310]
             Cell surface molecules and ligands
              Cell adhesion molecules: Ig superfamiy
               SIGLEC family
                CD33 (SIGLEC3)
                 D12152  Eluvixtamab (USAN)
///
